CDK12 and neoplasm: CDK12‐mutated prostate cancer patients also had a higher tumour mutation burden (TMB) than CDK12 wild‐type prostate cancer patients (Figure 1G), which leads to an increased generation of neoantigens that may result in a better response to immune therapies.19